Limited impact of expensive drugs

Only 22 of 95 drugs assessed since 2022 by the National Institute for Value and Technologies in Healthcare are expected to deliver more than one additional year of life in full health, the value-for-money unit UHP said. Similarly, more than half of drugs entering the German market in 2011–17 showed no benefit versus existing treatment, according to the local medicines agency. Typically very expensive, such drugs extend life by only a few months, explaining insurers’ caution in reimbursing them.

(UHP)